An EphA2 small-molecule inhibitor could be used successfully to reverse cetuximab resistance in CRC cells by inducing apoptosis and cell cycle G1–G2 arrest and inhibiting the MAPK and AKT pathways [283]. This evidence concerns the gene EPHA2 and colorectal carcinoma.